Denali Therapeutics

$17.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.31 (-1.71%) Today
$0.00 (0.00%) As of 4:30 PM EDT after-hours

Why Robinhood?

You can buy or sell DNLI and other stocks, options, ETFs, and crypto commission-free!

About DNLI

Denali Therapeutics Inc. Common Stock, also called Denali Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Read More Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Employees
179
Headquarters
San Francisco, California
Founded
2013
Market Cap
1.71B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
251.51K
High Today
$18.52
Low Today
$17.70
Open Price
$18.00
Volume
252.21K
52 Week High
$28.87
52 Week Low
$13.78

Collections

DNLI Earnings

-$0.61
-$0.14
$0.32
$0.79
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.